News Chi-Med agrees R&D partnership with Inmagene China’s Chi-Med and Inmagene Biopharmaceuticals have agreed a strategic partnership to develop preclinical drug candidates for potential treatment of several immunological diseases.
News AstraZeneca files Imfinzi for groundbreaking lung cancer use AZ also unveils promising results from early-stage lung cancer combination